Skip to content. | Skip to navigation

Personal tools
You are here: Home Biosafety Institutional Biosafety Committee (IBC)

Institutional Biosafety Committee (IBC)

by Sanchez,Jason last modified Mar 28, 2013 10:06 AM

In compliance with NIH Guidelines and University policies, an Institutional Biosafety Committee (IBC) exists and functions at the University of Louisville (UofL). The University's Institutional Biosafety Committee reviews all institutional activities involving the use of biohazardous agents and recombinant and synthetic nucleic acid molecules that require approval for "biosafety activities" as described in current governmental regulatory requirements. These regulatory requirements include, but are not limited to, the National Institutes of Health (NIH) Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines), the Centers for Disease Control and Prevention (CDC) Guidelines, and the Occupational Safety and Health Administration (OSHA) regulations and compliance directives as adopted and adhered to by KYOSH.


The Institutional Biosafety Committee's charge is to ensure that all persons, procedures and facilities involving the use of biological agents, recombinant or synthetic nucleic acid molecules and large scale activities meet the best interests of laboratory safety, effective research, as well as the environment and general public. The Institutional Biosafety Committee is appointed by and reports to the Executive Vice President of Research. The composition of the committee meets the requirements as specified in the NIH Guidelines and includes four community members that are not affiliated with UofL. The Department of Environmental Health and Safety (DEHS) provides the necessary administrative support for the functions and business of the Institutional Biosafety Committee.


IMPORTANT! - Effective March 5, 2013, the NIH Guidelines for Research Involving Recombinant DNA Molecules becomes the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules. The Institutional Biosafety Committee (IBC) advises investigators that all work involving biological and/or biohazardous agents, recombinant or synthetic nucleic acids, human gene therapy, creation of transgenic animals, use of human-derived or non-human primate materials, (i.e. blood, body fluids, tissues or cell lines) and CDC or USDA Select Agents and Toxins must be registered with the IBC.  For additional information on NIH Guideline changes: NIH-FAQs



Document Actions
Personal tools